Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues

AIDS

Volumn 22, Issue 17, 2008, Pages 2395-2398

  Poveda, Eva ^a   De Mendoza, Carmen ^a   Pattery, Theresa ^b   Del Mar González, María ^a   Villacian, Jorge ^b   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; STRUCTURAL GENE; VIRUS MUTATION;

ANTI-HIV AGENTS; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 56549101100     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32831692fb     Document Type: Article

References (13)

1. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC-125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant HIV type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
2. Madruga J, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomised, double-bind, placebo-controlled trial. Lancet 2007; 370:29-38.
3. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
4. Vingerhoets J, Buelens A, Peeters M, Picchio G, Tambuyzer L, Van Marck H, et al. Impact of baseline NNRTI mutations on the virological response to TMC-125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther 2007; 12 (Suppl):34.
5. Hirsch M, Günthard H, Schapiro J, Brun-Vézinet F, Clotet B, Hammer S, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
6. Hertogs K, de Bethune M, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant HIV type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42:269-276.
7. Peeters M, Nijs S, Vingerhoets J, Tambuyzer L, Woodfall B, de Bethune M, et al. Determination of phenotypic clinical cut-offs for etravirine: pooled week 24 results of the DUET-1 and DUET-2 trials. Antivir Ther 2008; 13 (Suppl):A133.
8. Poveda E, Garrido C, de Mendoza C, Corral A, Cobo J, González- Lahoz J, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of nonnucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 60:1411-1413.
9. Scott C, Grover D, Nelson M. Is there a role for etravirine in patients with nonnucleoside reverse transcriptase inhibitor resistance? AIDS 2008; 22:989-992.
10. Picchio G, Vingerhoets J, Staes M, Tambuyzer L, Bacheler L, Pattery T, et al. Prevalence of TMC125 resistance-associated mutations in a large panel of clinical isolates [abstract 866]. In: 15th Conference on Retroviruses and Opportunistic Infectious; 3-6 February 2008; Boston, Massachusetts; 2008.
11. Llibre J, Santos J, Puig T, Blanco A, Paredes R, Mothe B, et al. Prevalence of mutations with effect on virological response to etravirine in routine clinical samples [abstract 868]. In: 15th Conference on Retroviruses and Opportunistic Infectious; 3-6 February 2008; Boston, Massachusetts; 2008.
12. Vingerhoets J, Peeters M, Azijn H, Tambuyzer L, Hoogstoel A, Nijs S, et al. An update of the litt of NNRTI mutations associated with decreased virologic response to etravirine: multi-variate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther 2008; 13 (Suppl):A23.
13. Gupta S, Fransen S, Paxinos E, Huang W, Stawiski E, Petropoulos C, et al. Infrequent occurrence of mutations in the C-terminal region of reverse transcriptase modulates susceptibility to RT inhibitors. Antivir Ther 2006; 11 (Suppl):143.